We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Drug Companies Cite Weaknesses in FDA Draft Guidance on Generic Topical Patches

Drug Companies Cite Weaknesses in FDA Draft Guidance on Generic Topical Patches

September 23, 2016

Earlier this summer the FDA recommended a five-point scale to rate topical patch adhesion for drugmakers submitting abbreviated new drug applications (ANDA). However, the recommendations have only raised more questions.

The draft guidance, released in May, is used to determine whether the entire surface of a topical patch adheres to the skin for the duration of wear, according to the FDA. The scale includes:

  • 0 = ≥ 90% adhered (essentially all of the patch is on the skin);
  • 1 = ≥ 75% to < 90% adhered;
  • 2 = ≥ 50% to < 75% adhered;
  • 3 = > 0% to < 50% adhered; and
  • 4 = 0% adhered (completely detached).

The community largely has been positive about the new scale. However, commenters want more detail on it as well as information on second and third generation products.

Perrigo takes issue with the FDA request for photographic documentation of patches so they can be graded. Perrigo says it is unclear what qualitative issues of an adhesion study photographic documentation would assess other than to confirm that the patch was applied flat against the skin to the correct application site.

Additionally, Perrigo adds that if four or more photographs are required to assess all of the edges of a patch, a study of 200 patients could mean that 7,200 photos will need to be taken.

AstraZeneca a Maryland-based company, said the document would benefit from more clarification on whether second- and third-generation transdermal systems are intended to be covered by this guidance or if there will be other standards/guidance to be considered.

Apotex, a Canadian generic drugmaker, requested further clarification on the acceptability of the adhesion studies that have already been designed and conducted based on the existing individual product-specific guidance documents that were released before this draft became available.

Order your copy of Achieving ANDA Success: Working with the FDA to Win First-Cycle Approval today — applicants who get it right the first time can get their products to market quicker.

View today's stories

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing